Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Monetary Wellness: Planning Tips for Independence from the rat race - 2Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 3Five killed in Israeli air strikes on tents near Khan Younis, medics say
- 4UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- 5Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- Treasure trove found in Egyptian tomb solves ancient mystery
- How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- How will the universe end?
- Man triggers smoke bomb during failed crypto robbery
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya
- 10 Moves toward Start Your Own Effective Business
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
